NCT00809679View on ClinicalTrials.gov

Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia

PHASE2TerminatedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Postherpetic Neuralgia

Interventions

DRUG

T-62 Dose 1

Capsule dosage form 100 mg bid

DRUG

T-62 Dose 2

Capsule dosage form 200 mg bid

OTHER

Placebo

Capsule dosage form placebo bid

Trial Locations (13)

Unknown

Tucson

Westlake Village

Bradenton

Naples

New Port Richey

Sunrise

Tampa

Lexington

Albuquerque

Winston-Salem

Oklahoma City

San Antonio

Spokane

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY